Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.39 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.39 |
| ▸ | FDPS | P14324 | 8/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27212835 | 1.00 | CES2 (0.41) | CES2MEN1MAPTKMT2AATM | |
| SCHEMBL31319781 | 0.98 | DGAT1 (0.39) | CES2MEN1MAPTKMT2AATM | |
| SCHEMBL28134679 | 0.92 | DGAT1 (0.40) | CES2MEN1MAPTKMT2AATM | |
| SCHEMBL17381369 | 0.90 | GPR84 (0.55) | MEN1MAPTKMT2A | |
| SCHEMBL18612496 | 0.88 | CES2 (0.46) | CES2MEN1MAPTKMT2AATM | |
| SCHEMBL19509962 | 0.88 | CES2 (0.46) | CES2MEN1MAPTKMT2AATM | |
| SCHEMBL12223368 | 0.88 | DGAT1 (0.38) | CES2MEN1MAPTKMT2AATM | |
| SCHEMBL24042514 | 0.87 | MAPT (0.36) | CES2MEN1MAPTKMT2AATM | |
| SCHEMBL24042509 | 0.87 | TSHR (0.48) | MEN1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL19510184 | 0.86 | CES2 (0.44) | CES2MEN1MAPTKMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4682138-A1 | COMPOUND OR SALT THEREOF, LIPID COMPOSITION, PHARMACEUTICAL COMPOSITION, AND DELIVERY CARRIER | FUJIFILM Corporation (JP) | 2026-01-21 | — | — | EP | disclosed |
| US-20260001834-A1 | COMPOUND OR SALT THEREOF, LIPID COMPOSITION, PHARMACEUTICAL COMPOSITION, AND DELIVERY CARRIER | FUJIFILM CORPORATION (JP) | 2026-01-01 | — | — | US | disclosed |
| WO-2024190817-A1 | COMPOUND OR SALT THEREOF, LIPID COMPOSITION, PHARMACEUTICAL COMPOSITION, AND DELIVERY CARRIER | 富士フイルム株式会社 | 2024-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001834-A1 | COMPOUND OR SALT THEREOF, LIPID COMPOSITION, PHARMACEUTICAL COMPOSITION, AND DELIVERY CARRIER | NSUN3, NPC1L1, TLR9 | CES2 1174/4885MEN1 3190/4885MAPT 3463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.